# How Ipamorelin Works in the Research: Receptor, Pathway, Pulse > How does ipamorelin peptide work? A plain, cited walk through the GHS-R1a ghrelin-receptor mechanism, the GH pulse, and how it differs from sermorelin and tesamorelin. ## Start here If you have wondered what does ipamorelin peptide do at the level of cells, here is the plain version. Ipamorelin is a tiny five-amino-acid peptide that fits into one specific lock on the pituitary gland, the ghrelin receptor (its technical name is GHS-R1a). The ghrelin receptor is normally triggered by ghrelin, the body's hunger hormone. When ipamorelin flips that switch, the pituitary releases a short pulse of growth hormone [1]. The special thing, proven in 1998, is that it pulls this one lever cleanly: it raises growth hormone without raising the stress hormone cortisol or prolactin, which the older peptides in its class do not manage [1]. Because it works through a different door than peptides like sermorelin and tesamorelin, it is often paired with them. Below, the mechanism step by step, then how it compares to its cousins. ## What is ipamorelin peptide The ipamorelin peptide is a wholly synthetic pentapeptide, five amino acids in the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, with a molecular weight of about 712 Da [1]. It was derived from the earlier peptide GHRP-1 by removing a central dipeptide, and the unusual building blocks (alpha-aminoisobutyric acid at position 1, plus D-form amino acids) make it resistant to the enzymes that would otherwise break it down [1]. It is not a natural human peptide; it is a designed mimic of ghrelin that targets the ghrelin receptor. Its development code was NNC 26-0161, originated by Novo Nordisk [1]. ## Step by step: from receptor to growth-hormone pulse The mechanism is a short chain of events. Ipamorelin binds the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) on pituitary somatotrophs, the growth-hormone-producing cells [1]. That binding activates the Gq/PLC signaling pathway, which raises calcium inside the cell, and the calcium rise triggers release of a stored pulse of growth hormone [1]. In humans, that pulse is a single discrete spike peaking about 40 minutes after dosing, and the peptide is mostly cleared within a couple of hours (terminal half-life around 2 hours) [2]. Downstream, growth hormone can prompt the liver to make IGF-1, though in short rodent studies IGF-1 was not always raised, suggesting some effects are local and pulse-driven [4]. ## Why it is paired with a GHRH analog Ipamorelin works through a different pathway than the GHRH analogs, which is the whole point of combining them. GHRH analogs such as CJC-1295 act on the GHRH receptor through the cAMP pathway, while ipamorelin acts on the ghrelin receptor through the calcium pathway [1]. Activating both at once is additive. Supporting the physiology: pulsatile growth-hormone secretion persisted even during continuous CJC-1295 stimulation, so a steady GHRH signal does not flatten the natural rhythm a pulsatile ghrelin-receptor agonist provides [9], and CJC-1295 produces durable IGF-1 elevation [10]. This complementary-pathway logic, not a combination trial, is what underpins the popular pairing [3]. ## Ipamorelin vs sermorelin Ipamorelin vs sermorelin is a contrast of two different receptors. Sermorelin is a GHRH analog: it mimics growth-hormone-releasing hormone and acts on the GHRH receptor [1]. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist acting on a different receptor entirely [1]. They raise growth hormone by separate, complementary pathways, which is why a GHRH analog and a ghrelin-receptor agonist are sometimes combined rather than chosen one-or-the-other [9]. A practical regulatory difference: sermorelin had an approved-drug history, whereas ipamorelin has never been approved for any indication [3]. ## Ipamorelin vs tesamorelin Ipamorelin vs tesamorelin is the same receptor contrast with a different comparator. Tesamorelin is a stabilized GHRH analog acting on the GHRH receptor [1]; ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist acting on the ghrelin receptor [1]. Because they work through complementary pathways, they are mechanistically combinable rather than interchangeable [9]. The evidence bases differ sharply: tesamorelin reached regulatory approval for a specific indication, while ipamorelin's only Phase 2 trial missed its endpoint and it has no approved use anywhere [3]. --- Newest-studies-first, every figure pinned to its source: an independent ipamorelin reading desk, never a clinic, a prescription, or a checkout.